Jaguar Health (NASDAQ: JAGX) is a commercial-stage pharmaceutical company focused on developing plant-based prescription medicines for gastrointestinal conditions in humans and animals. Its key products include Mytesi, Gelclair, and Canalevia-CA1, while its development pipeline remains focused on crofelemer for rare intestinal failure disorders, including microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
On May 20, 2026, Jaguar Health reported its consolidated first-quarter 2026 financial results. Total net revenue increased to $20.27 million from $2.21 million in the same quarter of 2025, representing 816% year-over-year growth. This increase was primarily driven by license and grant revenue of $19.07 million, including revenue recognized from the company’s U.S. licensing agreement with Woodward Specialty, an affiliate of Future Pak, for Mytesi and Canalevia-CA1.
Prescription product revenue, however, declined to approximately $1.2 million from $2.17 million in Q1 2025. The decrease reflects Jaguar’s January 2026 royalty-free license agreement with Future Pak, under which U.S. revenues from Mytesi and Canalevia-CA1 are directed to Future Pak as Jaguar shifts its strategic focus toward rare-disease crofelemer development.
The company reported a net loss attributable to common stockholders of $7.02 million, improving from a loss of $10.46 million in the prior-year quarter. Net loss per share was $13.60. Although the loss narrowed, Jaguar remains unprofitable, and its negative price-to-earnings ratio reflects those continuing losses.
Operating results improved meaningfully during the quarter. Jaguar reported income from operations of $10.18 million, compared with a loss from operations of $9.42 million in Q1 2025. The improvement was largely due to license revenue from the Future Pak agreement and reduced operating expenses, including lower sales and marketing costs following the licensing transition.
Financial risk remains elevated. StockAnalysis lists Jaguar Health’s current ratio at 0.50 and debt-to-equity ratio at approximately -2.16, indicating weak short-term liquidity and negative shareholders’ equity. A negative debt-to-equity ratio should be interpreted as a balance-sheet warning rather than a normal leverage measure.
Despite these challenges, Jaguar Health continues to focus on crofelemer development for rare-disease intestinal failure indications. The company said two crofelemer presentations involving pediatric intestinal failure patients with MVID and SBS-IF are scheduled for the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition Meeting in June 2026.
